Popular Biotech News, Healthcare News and Pharma News

16:25 EDT 30th March 2017 | BioPortfolio

Prima BioMed (PRR) - Initial LAG-3 combo data presented

Edison Investment Research - Pharmaceutical & healthcare - Prima BioMed: Prima BioMed has presented encouraging early signs of efficacy from the TACTI-mel trial of IMP321 in combination with Keytruda, with one of the six melanoma patients in the first (1mg/kg) cohort experiencing a complete response. Recruitment in the second cohort is complete and the final cohort is expected to be fully recruite...

Pernix Therapeutics Holdings Inc PTX Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 21022017] Prices from USD $250

SummaryPernix Therapeutics Holdings Inc Pernix Therapeutics is a pharmaceutical company that manufactures, markets generic pharmaceutical products for pediatric market. The company provides branded and generic pharma products. It provides products in allergy, upper respiratory, including nasal, chest congestion and cough, antibiotics and dermatology areas. Pernix Therapeutics provides patient assi...

Bellicum Pharmaceuticals Inc BLCM Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 23022017] Prices from USD $250

SummaryBellicum Pharmaceuticals Inc Bellicum is a clinical stage biopharmaceutical company that focused on the discovery and development of cellular immunotherapies for the treatment of cancer including both hematological cancers and solid tumors, and orphan inherited blood disorders. The company develops its product candidates through its chemical induction of dimerization CID technology platform...

Rexahn Pharmaceuticals Inc RNN Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 21022017] Prices from USD $250

SummaryRexahn Pharmaceuticals Inc Rexahn Pharmaceuticals formerly Corporate Road Inc., is a clinical stage biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutics for the treatment of cancer. The company's anticancer drug candidates include Archexin, which is intended for the treatment of pancreatic cancer; RX3117, for the treatment of pa...

Rubicon Organics Receives Municipal Permit for the Cultivation & Manufacturing of Cannabis in Greenfield, California

Rubicon Organics (“Rubicon” or the “Company”) is pleased to announce that its application to the City of Greenfield for a municipal cultivation and manufacturing permit has been approved. The Company plans to develop a high-tech greenhouse facility of approximately 80,000 square feet. This facility, in addition to the Company’s Washington State f...

EnteroMedics Inc ETRM Medical Equipment Deals and Alliances Profile [Updated: 23012017] Prices from USD $250

SummaryEnteroMedics Inc Enteromedics is a medical device company that offers therapeutic products for gastrointestinal and metabolic diseases. The company designs and develops medical devices for the treatment of obesity and other disorders. It develops and provides VBLOC therapy used in the treatment of gastrointestinal and metabolic diseases. EnteroMedics offers maestro system, components, and o...

Exelixis Inc EXEL Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 16032017] Prices from USD $250

SummaryExelixis Inc Exelixis is a biopharmaceutical company. It focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company has two advanced product candidates: Cometriq Cabozantinib, an inhibitor of multiple receptor tyrosine kinases; and Cobimetinib GDC0973/XL518, a potent, highly selective inhibitor of methyl ethyl ketone MEK. The compan...

Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment

Company targeting context-dependent vulnerabilities in cancers for patients without effective treatment options Third Rock Ventures, LLC today announced the launch of Tango Therapeutics, a new cancer therapeutics company discovering and developing novel medicines designed to target cancer vulnerabilities beyond mutated oncogenes to deliver transformati...

Polyphor develops the elastase inhibitor POL6014 for rare lung diseases using PARI Pharma’s eFlow® Technology inhalation device

Allschwil, Switzerland, January 9, 2015. Polyphor Ltd, a privately held pharmaceutical company specialized in the discovery and development of macrocycle drugs, today announced the signing of a licensing agreement with PARI Pharma, Starnberg, Germany, to use the eFlow® Technology nebulizer for the administration of POL6014, a highly potent and selective inhibitor of neutrophil elastase. ...

Enter Tata Capital as Sequoia exits Sai Life?

Venture capital firm Sequoia, is said to have exited Sai Life Sciences, an Indian contract research organization (CRO) that provides discovery and developmental support services to biotech and pharmaceutical companies.

Pharmaxis grants BI option on NASH program PXS4728A

For a fee of €1.25mm ($1.33mm), Pharmaxis Ltd. granted Boehringer Ingelheim GMBH an option to license exclusive worldwide rights to its Phase I non-alcoholic steatohepatitis (NASH) candidate PXS4728A, an inhibitor of semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1 (VAP-1)).

Vertex gains despite mixed Orkambi briefing docs

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) gained $2.36 to $127.41 on Friday despite mixed comments by FDA reviewers on Orkambi, the company's combination of lumacaftor (VX-809) and Kalydeco ivacaftor, to treat cystic fibrosis patients homozygous for the F508 CFTR mutation. The reviewers said Orkambi had a statistically significant but "modest" 2.6-3% improvement on percent predicted forced expirat...

LabQuiz: Immunoassays

Do you have an affinity for immunoassays or does the thought of antibodies immobilize you? Try your hand at our Immunoassay Quiz to find out!

CheckMate-057 Trial: The Future of PD-L1 as a Biomarker

Dr H. Jack West discusses one of the hottest topics at ASCO 2015: the evolving role of PD-L1 as an immunotherapy biomarker. Medscape Oncology

ResMed to acquire Curative Medical

Sleep disorder device supplier ResMed (ASX:RMD) today signed a definitive agreement to acquire its Chinese counterpart Curative Medical. According to ResMed CEO Mick Farrell, the partnership between the two companies will “help many millions of people in China suffering from sleep-disordered breathing and chronic obstructive pulmonary disease”. On completion of the transaction, which is expec...

Humacyte's Series B round brings in $150mm

Humacyte Inc. (human tissue-based products for regenerative medicine and vascular surgery) raised $150mm through its Series B round. New and returning investors took part including Access Industries, Bangkok Bank Public Co. Ltd., Brady Dougan, Pacific Eagle Asset Management, Reignwood Group, and Gavril Yushvaev. Credit Suisse was the placement agent.

PTAB rejects Bass' Imbruvica challenge

The Patent Trial and Appeals Board of the U.S. Patent and Trademark Office denied an inter partes review (IPR) petition from Kyle Bass' Coalition for Affordable Drugs challenging a patent covering Imbruvica ibrutinib from AbbVie Inc. (NYSE:ABBV).The coalition had challenged U.S. Patent No. 8,754,090. The patent is one of 12 Orange Book-listed patents covering Imbruvica and expires June 3, 2031.PTA...

Evolution: Doing the locomotion

Kevin Padian assesses a study on how animals came to fly, wade, creep and glide.

FDA approves Gilead’s Odefsy for treatment of HIV-1 infection

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the treatment of HIV-1 infection in certain patients. read more

World Congress Announces Agenda for The 340B Summit

Boston, MA, March 22, 2016 --( World Congress has announced the agenda for The 340B Summit taking place at the Hilton Philadelphia at Penn’s Landing in Philadelphia. Covered entities will gather at this inaugural event to determine the impact of revised mega-guidance, discuss strategies for managing compliance, and evaluate the financial risks and opportunities of the 340B program....

Mandrola Previews American College of Cardiology 2016 Meeting

Dr Mandrola peruses the program for hidden gems and reviews the late-breaking clinical-trial line-up. on Medscape

Regeneron, Bayer deal

ProvayBlue given FDA new drug application status

Pharma development company, Provepharm’s ProvayBlue (methylene blue) Injection has been given New Drug Application status from the US Food and Drug Administration (FDA) under its accelerated approval regulations

Corcept Therapeutics - Near Term Milestones for the Comeback Kid

Corcept Therapeutics (CORT) has some important milestones arriving within the next three months. The ASCO abstracts were also recently published online. While the actual poster presentation will contain updated information the early signals are still relevant.  If you wish to be updated on Corcept, you may view our commentary on its Q1-2016 results.Phase 1 Safety Results – Hormone Resistant...

Samsung Bioepis: the creation of a biosimilar giant that is ‘here to stay’

The biosimilars pipeline of the South Korean company Samsung Bioepis would be highly impressive if it…

Herbalife Fined $200M, but FTC Says It's Not a Pyramid Scheme

Herbalife Ltd. is to pay $200 million in a settlement with the Federal Trade Commission that will enable the company to avoid being classified as a pyramid scheme, a victory in its long-running battle with activist investor William Ackman.

Inner Engineering Total: Technologies for Wellbeing Offered in Dayton September 15-18, 2016

Dayton, OH, August 31, 2016 --( There will be a 4-day Inner Engineering Total program in Dayton, September 15-18, 2016 at the Mangan Banquet Center in Beavercreek, OH. Designed by Sadhguru, a yogi, mystic, and a realized Master, the program will offer the Shambhavi Mahamudra, an ancient yogic practice that traditionally has only been available to a select few after many years of intense ...

IL-34: New, possible target to tackle drug-resistant cancer cells

Chemoresistant lung cancer cells suppress immune functions and strengthen resistance to chemotherapy by producing interleukin-34 (IL-34)—a type of cytokine, a team of researchers has discovered.

Mauro Janoski, M.D., F.A.C.P. Joins the Oncology Institute of Hope and Innovation

The Oncology Institute of Hope and Innovation welcomes Dr. Janoski to their team of specialists Anaheim, CA (PRWEB) October 16, 2016 Dr. Mauro Janoski is an empathic, compassionate, updated, and experienced physician who welcomes patients from all walks of life. Dr. Janoski attended medical school at the Evangelical School of Medicine for three years and completed his last year at the University...

Endo finds buyer for Charlotte manufacturing plant

Endo International has signed an agreement to sell its facility in Charlotte, North Carolina to an unnamed buyer that will take on 125 workers currently employed at the site.

DHL Appoints New Head for its Life Sciences & Healthcare Sector

DHL Customer Solutions & innovation has appointed Scott Allison as President, DHL Life Sciences & Healthcare. In his new role, Scott will be in charge of global key account management for DHL’s largest customers in Life Sciences and Healthcare, driving growth and development of the sector and overseeing strategy and solutions development in addition to his commercial duties. Previou...

Insulin Market in Peru to 2019 Market Size, Development, and Forecasts Prices from USD $541

The industry report Insulin Market in Peru to 2019 Market Size, Development, and Forecasts offers the most uptodate market data on the actual market situation, and future outlook for insulin in Peru. The research includes historic market data from 2008 to 2014 and forecasts until 2019 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, ana... Launches DRTV Campaign with Naples Soap Company and its Product Managers announce the DRTV campaign launch with Naples Soap Company St. Petersburg, Florida (PRWEB) January 05, 2017 Kevin Harrington, one of the original Sharks from hit reality series Shark Tank, and the Product Managers of are pleased to announce the launch of a new DRTV campaign with Naples Soap Company. More than 30 million Americans suffer from ...

AstraZeneca rejigs MYSTIC lung cancer study

It’s been a busy morning at AstraZeneca PLC (LON:AZN). The UK drug giant this morning announced that it has refined its MYSTIC trial, has submitted an application to expand its NEPTUNE study, and has initiated a new phase III PEARL trial in Asia. The MYSTIC trial – arguably the ‘big one’ for Astra – is designed to assess the benefit of durvalumab monotherapy as well as a durvalumab and...

What to Do with Your Amputated Leg

You own your body parts when they’re inside you—but take them out, and it gets complicated -- Read more on

Cerulean Pharma Inc CERU Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryCerulean Pharma Inc Cerulean formerly Tempo Pharmaceuticals, Inc. is a biopharmaceutical company that develops products to improve treatment options for people living with cancer. The company offers nanoparticle drug conjugates to provide cancer treatments. Its products include NDC with a camptothecin payload and NDC with a docetaxel payload. Cerulean's NDC with a camptothecin payload provi...

ADNOC to Restart Fire-Hit Ruwais Refinery

Abu Dhabi National Oil Company (ADNOC) said on Jan. 17 it hoped to restart its fire-impacted Takreer refinery at Ruwais, Abu Dhabi in the United Arab Emirates before the end of this week. According to reports, the blaze that broke out on Jan. 11 forced the shutdown of about half the facility, which has capacity estimated at 800,000--1 million bbl/d of crude oil.

Smoke Evacuation System Market by Product Smoke Evacuators Portable Stationary, Pencils, Wands, Tubings, Accessories, Application Laser, Ultrasonic Electrosurgery Units, EndUser Hospital, Surgical Centers, Clinics Global Forecast to 2020 Prices from US

The global smoke evacuation system market is estimated to grow at a CAGR of 5.6% from 2015 to 2020. Although mature markets such as North America and Europe hold larger shares in the market in 2015, the AsiaPacific region is poised to grow at the highest CAGR of 7.1% in the next five years. Factors such as the growing popularity of cosmetic surgery, presence of a large patient population, governme...

Agilent Technologies 7683 Series AutoSampler Tray G2614A HP

$2,400.00End Date: Tuesday Feb-21-2017 15:14:47 PSTBuy It Now for only: $2,400.00Buy It Now | Add to watch list Biotech365 : Agilent Technologies 7683 Series AutoSampler Tray G2614A HP BioMarketplace You want to propose your products or a Biotech Company, a … Continue reading → Cet article Agilent Technologies 7683 Series AutoSampler Tray G2614A HP est apparu en premier sur Biotec...

MÄRKTE EUROPA/Aufwärtsbewegung verliert Schwung - Actelion haussieren

Von Thomas Leppert FRANKFURT (Dow Jones)--Nach dem Plus der vergangenen Tage verlor die Aufwärtsbewegung an den Börsen am Donnerstag an Schwung. Der DAX schloss zwar noch 0,4 Prozent fester bei 11...

North Africa Cloud Managed Services Market by Service Types Business Services, Network Services, Security Services, Data Center Services, Mobility Services Global Forecast to 2015 2020 Prices from USD $7150

The organizations in the 21st century need to allow thirdparty service providers to perform routine business services for them to drive down operational costs, strengthening customer relationships, and improving financial management. Managed services mean that a company hands over a part or the entire management of its network infrastructure, applications, and security to experts such as service p...

Behavioral Treatments for Children with Obesity: Where Are the Fathers?

Fathers were not participants in most trials of behavioral interventions for obesity in children and youth.

Bial Sells Allergic Immunotherapy Business

  Life Sciences Jobs   ...

Syneron seeks buyer for $322m

Apax Partners is among those interested in the Israeli esthetic medicine company.

Alkermes' MDD candidate heads for FDA submission

Alkermes plc (NASDAQ:ALKS) plans to submit an NDA next half for ALKS 5461 as adjunctive treatment of major depressive disorder. The candidate combines samidorphan (ALKS 33), which is a mu opioid receptor (OPRM1; MOR) antagonist, with buprenorphine.In October, the higher of two doses of ALKS 5461 met the primary endpoint of the Phase III FORWARD-5 trial. The candidate had failed in two previous Pha...

Agilent Technologies 7683 Series AutoSampler Tray G2614A with G2614-60610 cable

$1,975.00 (8 Bids)End Date: Saturday Feb-25-2017 8:26:55 PSTBid now | Add to watch list Biotech365 : Agilent Technologies 7683 Series AutoSampler Tray G2614A with G2614-60610 cable BioMarketplace You want to propose your products or a Biotech Company, a Biotech Tool … Continue reading → Cet article Agilent Technologies 7683 Series AutoSampler Tray G2614A with G2614-60610 cable est...

Cytokine Concentration Correlates with Diabetic Nephropathy

Diabetic nephropathy (DN) is a major microvascular complication of diabetes mellitus, and it is the leading cause of end-stage renal...

Quick Search